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Cystic angiomatosis is a rare condition of disseminated multifocal hemangiomatous and/or lymphan-
giomatous lesions of the skeleton with possible visceral organ involvement. The cause of this condition is
unknown. Patients with cystic angiomatosis may remain asymptomatic or experience bone pain, even in
the absence of pathologic fracture. In the present study we described a 20-year old men, in otherwise ex-
cellent health, had a 2-year history of cervical and dorsal back pain. Radiographs of the column showed
the presence of multiple cystic lesions in the cervical, dorsal and lumbar vertebral body. A triple-phase
whole-body bone scan demonstrated focal increased up-take within, with no other abnormalities. Destruc-
tion of bone was confirmed by CT scans and MRI scans showed angiomatous soft tissue formation. A
bone biopsy specimen appeared as a simple cyst or multiple communicating cysts. Serum calcium and
phosphorous levels PTH and Vitamin D metabolites at the presentation were within the respective
rangers. Serum bone alkaline phosphatase was elevated (31.4 U/L; reference range 10-25) and des-
oxypiridinoline (DPD) in the normal range. For additional studies, we assessed the serum concentrations
of the osteoclastic regulators osteoprotegerin (OPG) and osteopontin (OPN) at the baseline and during
the follow-up by ELISA (R&D System, USA; Immundiagnostik, Germany). At the baseline OPN and OPG
levels were high (OPN:16±0.5 ng/ml reference value: 5.9±0.6 and OPG 125±0.34 pmol/ml reference val-
ue 0-30). Patient started an intravenous bisphosphonate infusion (30 mg pamidronate) every month. A
follow-up after 6 months therapy showed an improve of mobility and back pain of the patient. Imaging
studies including conventional X-ray and CT scans after 3 and 6 months of treatment did not show and
progression of bone destruction. After initiation of bisphosphonate tretment serum bone alkaline phos-
phatase levels normalized. In addition OPN and OPG decreased significantly. In conclusion, an immedi-
ate clinical improvement of local pain, an improvement of metabolic resorption and a stable clinical, radio-
logical picture during the first 6 months of follow-up suggests effectiveness of pamidronate treatment
alone. Longer-term follow-up and additional studies employing bisphosphonates in skeletal cysitic an-
giomatosis will help to evaluate this therapeutic approach in further detail.
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